This website is for US healthcare professionals

close-icon

Log In to Bolder Science

or

Don't have an account? Sign Up

close-icon

Please enter your email address.

You will receive a link to create a new password via email.

Log In

close-icon

Create an Account

or
  • 8 characters minimum
  • First character may not be a number
  • Last character may not be a number
close-icon

Welcome and thank you for creating an account!

At Bolder Science, we want your clinical trial search experience to be the best it can be. Complete the following prompts to easily find the trials you are interested in and see trials recruiting near you. You can adjust these selections in your dashboard after creating your account.

Condition Categories

Condition categories are pulled directly from ClinicalTrials.gov. Choose 1 or more condition categories that you are interested in:

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

Set a default location

Postoperative Analgesia in Laparoscopic Abdominal Surgery After Exparel Via TAP or Local Infiltration

  • Clinicaltrials.gov identifier

    NCT03927326

  • Recruitment Status

    Not yet recruiting

  • First Posted

    April 25, 2019

  • Last update posted

    April 25, 2019

Study Description

Brief summary:

This study evaluates differences in how administering liposomal bupivacaine via two different methods affects postoperative pain control in laparoscopic abdominal surgery patients. Half the participants will receive liposomal bupivacaine via a transverses abdominis plane block while the other half will receive liposomal bupivacaine via local infiltration.

  • Condition or Disease:Pain, Postoperative
    Anesthesia, Local
    Anesthesia; Functional
    Anesthesia
    Opioid Use
  • Intervention/Treatment: Drug: Exparel 266 MG Per 20 ML Injection
  • Phase: N/A

Detailed Description

Liposomal bupivacaine is a newer formulation of a local anesthetic that is commonly used for local infiltration, peripheral nerve blocks, and neuraxial anesthesia. This new formulation allows the effects of bupivacaine to last up to 72 hours as it is slowly released from a liposome. It is FDA approved for local infiltration and has recently been approved for interscalene blocks. A transversus abdominis plane block is a fascial plane block that is performed routinely for postoperative pain relief for some abdominal incisions. It is performed by placing local anesthetic between the internal oblique and transverses abdominis muscle planes where it will provide analgesia to several dermatomes of the abdomen in hopes of improving postoperative pain relief and reducing postoperative opioid requirement.

Study Design

  • Study Type: Interventional
  • Estimated Enrollment: 150 participants
  • Allocation: Randomized
  • Intervention Model: Parallel Assignment
  • Intervention Model Description: Unblinded randomized trial
  • Masking: Single (Outcomes Assessor)
  • Primary Purpose: Treatment
  • Official Title: On Postoperative Analgesic Requirements in Laparoscopic Colorectal Surgery Patients After Exparel Administration Via Transversus Abdominis Plane Block Versus Surgical Infiltration
  • Estimated Study Start Date: August 2019
  • Estimated Primary Completion Date: July 2020
  • Estimated Study Completion Date: July 2020

Arms and interventions

Arm Intervention/treatment
Experimental: Local infiltration
Liposomal bupivacaine (266mg) will be directly infiltrated by the surgeon into the surgical laparoscopic wound sites.
Drug: Exparel 266 MG Per 20 ML Injection
Liposomal bupivacaine
Experimental: Transversus abdominis plane block
Liposomal bupivacaine (266mg) will be used in a ultrasound guided transversus abdominis plane block.
Drug: Exparel 266 MG Per 20 ML Injection
Liposomal bupivacaine

Outcome Measures

  • Primary Outcome Measures: 1. 24 hour post operative opioid consumption [ Time Frame: 24 hours postoperative ]
    Listed in morphine daily equivalents.
  • Secondary Outcome Measures: 1. 12 hour post operative opioid consumption [ Time Frame: 12 hours postoperative ]
    Listed in morphine daily equivalents
  • 2. 48 hour post operative opioid consumption [ Time Frame: 48 hours postoperative ]
    Listed in morphine daily equivalents
  • 3. Pain intensity at 12 hours post operative [ Time Frame: 12 hours ]
    Self reported pain intensity by visual analog scale scored 0-10 (0 = no pain; 10 = worst pain imaginable)
  • 4. Pain intensity at 24 hours post operative [ Time Frame: 24 hours ]
    Self reported pain intensity by visual analog scale scored 0-10 (0 = no pain; 10 = worst pain imaginable)
  • 5. Hospital length of stay [ Time Frame: Until end of hospital stay, typically 3 days ]
    How long the patient requires their inpatient stay measured in days.

Eligibility Criteria

  • Ages Eligible for Study: 18 to 65 Years (Adult, Older Adult)
  • Sexes Eligible for Study: All
  • Accepts Healthy Volunteers: Yes

Criteria

Inclusion Criteria:

- Patients scheduled for elective laparoscopic colorectal surgery at UWMC requiring
inpatient stay

Exclusion Criteria:

- Patients on chronic pain mediations equaling or exceeding > 25 morphine daily
equivalents

- Patients allergic to bupivacaine

- Patients with ASA status IV, V, or VI

- Patients unable to consent

- Patients that are pregnant

- Patients that are incarcerated

- Patients receiving procedures in addition to laparoscopic colorectal procedure

- Patients on systemic anticoagulation precluding them from regional blocks

Contacts and Locations

Contacts

Contact: Alan Chang, MD 714-878-0850 achang5@uw.edu

Locations

Sponsors and Collaborators

University of Washington

Investigators

Principal Investigator: Vanessa Loland, MD University of Washington

More Information